Caricamento...
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of sym...
Salvato in:
| Pubblicato in: | Blood |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Hematology
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800543/ https://ncbi.nlm.nih.gov/pubmed/22700718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-399048 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|